✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Venus Remedies Ltd.

VENUSREM

Market Cap
₹578 Cr.
P/E
12.75

Venus Remedies Ltd.

  • Venus Remedies
  • Jenburkt Pharma
  • Prevest Denpro
FAQs on Venus Remedies Ltd. Shareprice

Venus Remedies has given better returns compared to its competitors.
Venus Remedies has grown at ~32.3% over the last 3yrs while peers have grown at a median rate of 18.95%

Yes, Venus Remedies is expensive.
Latest PE of Venus Remedies is 12.75, while 3 year average PE is 12.43.
Also latest EV/EBITDA of Venus Remedies is 7.86 while 3yr average is 6.93.

View FAQ's On Business
Growth Table
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Balance Sheet
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Cash Flow
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Quarterly Results
  • Venus Remedies Ltd.
  • Jenburkt Pharma
  • Prevest Denpro
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Venus Remedies Ltd. Financials

Balance sheet of Venus Remedies is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Venus Remedies is increasing.
Latest net debt of Venus Remedies is -₹78.41 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹94.71 Crs.

Yes, profit is increasing.
The profit of Venus Remedies is ₹45.33 Crs for TTM, ₹28.49 Crs for Mar 2024 and ₹26.57 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Venus Remedies latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech